Status:
COMPLETED
A Study of AK104, a PD-1/CTLA-4 Bispecific Antibody in Subjects With Recurrent/Metastatic Cervical Cancer
Lead Sponsor:
Akeso
Collaborating Sponsors:
Akesobio Australia Pty Ltd
Conditions:
Recurrent Cervical Cancer
Metastatic Cervical Cancer
Eligibility:
FEMALE
18+ years
Phase:
PHASE2
Brief Summary
This is a Phase 2, global, multicenter, open label, single arm study designed to evaluate the efficacy, safety, tolerability, pharmacokinetic (PK), and immunogenicity of AK104 monotherapy in adult sub...
Eligibility Criteria
Inclusion
- Able to provide written and signed informed consent and any locally required authorization obtained from the subject/legal representative.
- Women aged ≥18 years at the time of study entry.
- Subjects must have histologically or cytologically confirmed recurrent or metastatic squamous carcinoma or adenosquamous carcinoma of the cervix, and meet the following criteria: disease progression confirmed by radiologic imaging during or following prior platinum based doublet chemotherapy, with or without bevacizumab for recurrent or metastatic cervical cancer; No more than 2 prior systemic therapies in the recurrent or metastatic setting.
- Subjects must have measurable lesions according to RECIST v1.1. The presence of measurable lesions must be confirmed by the IRRC. A previously irradiated lesion is not considered measurable and cannot be selected as a target lesion.
- Available archived tumor tissue sample - block or a minimum of 10 unstained slides of formalin fixed paraffin embedded \[FFPE\] tissues - preferably from the most recent biopsy of a tumor lesion collected either at the time of or after the diagnosis of locally advanced, recurrent, and/or metastatic disease has been made.
- Eastern Cooperative Oncology Group performance status (ECOG PS) score of 0 or 1.
- Life expectancy ≥12 weeks.
- Adequate organ function.
Exclusion
- Concurrent enrollment in another clinical study, unless it is an observational (noninterventional) clinical study or the follow-up period of an interventional study.
- Histological types of cervical cancer other than squamous carcinoma and adeno-squamous carcinoma (eg, adenocarcinoma, small cell carcinoma, clear cell carcinoma, sarcoma, etc).
- Prior malignancy active within the previous 2 years except for the tumor for which a subject is enrolled in the study, and locally curable cancers that have been apparently cured, such as basal cell skin cancer, or carcinoma in situ of the breast.
- Brain/central nervous system (CNS) metastases.
- Clinically significant hydronephrosis, as determined by the investigator, not alleviated by nephrostomy or ureteral stent
- Active infections (including tuberculosis) requiring systemic antibacterial, antifungal, or antiviral therapy within 4 weeks prior to the first dose of investigational product.
- Known history of testing positive for human immunodeficiency virus (HIV) or known active acquired immunodeficiency syndrome.
- Known active hepatitis B or C infections (known positive hepatitis B surface antigen \[HBsAg\] result or positive hepatitis C virus \[HCV\] antibody with detectable HCV ribonucleic acid \[RNA\] results).
- Active or prior documented autoimmune disease that may relapse.
- History of interstitial lung disease or noninfectious pneumonitis, except for those induced by radiation therapies.
- Patients with clinically significant cardio-cerebrovascular disease.
- Unresolved toxicities from prior anticancer therapy, defined as having not resolved to NCI CTCAE v5.0 Grade 0 or 1, or to levels dictated in the eligibility criteria with the exception of toxicities not considered a safety risk.
- History of severe hypersensitivity reactions to other mAbs.
- Prior allogeneic stem cell transplantation or organ transplantation.
- Known allergy or reaction to any component of the AK104 formulation.
- Receipt of the following treatments or procedures: anticancer small molecule targeted agent within 2 weeks, radiation therapy within 2 weeks, other anticancer therapy within 4 weeks, any major surgery within 4 weeks, any other investigational product or procedure within 4 weeks, or agents with immunomodulatory effect within 2 weeks prior to the first dose of investigational product.
- Subjects with a condition requiring systemic treatment with either corticosteroids (\>10 mg daily doses of prednisone or equivalent) or other immunosuppressive medications within 14 days prior to the first dose of investigational product.
- Receipt of live attenuated vaccines within 30 days prior to the first dose of investigational product.
- Prior exposure to any experimental antitumor vaccines, or any agent targeting T-cell costimulation or immune checkpoint pathways (eg, anti-PD-1, anti-PD-L1, anti-PD-L2, anti-CTLA-4, anti-CD137 or anti-OX40 antibody, etc).
- Any condition that, in the opinion of the Investigator, would interfere with evaluation of the investigational product or interpretation of subject safety or study results.
Key Trial Info
Start Date :
July 15 2020
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
January 31 2023
Estimated Enrollment :
30 Patients enrolled
Trial Details
Trial ID
NCT04380805
Start Date
July 15 2020
End Date
January 31 2023
Last Update
February 28 2025
Active Locations (25)
Enter a location and click search to find clinical trials sorted by distance.
1
Womens Cancer Research Foundation
Newport Beach, California, United States, 92663
2
Sylvester Comprehensive Cancer Center
Miami, Florida, United States, 33136
3
BRCR Medical Center
Plantation, Florida, United States, 33322
4
Augusta University Medical Center
Augusta, Georgia, United States, 30912